Table 2. Study Treatment During Follow-up.
| Aflibercept (n = 100) |
Vitrectomy with panretinal photocoagulation (n = 105) |
|
|---|---|---|
| Had ≥1 vitrectomy, No. (%)a | 33 (33) | 8 (8) |
| Timing of first vitrectomy, No. (%)a | ||
| Between 0 and <24 wk | 14 (14) | 5 (5) |
| Between 24 and <52 wk | 9 (9) | 3 (3) |
| Between 52 and 104 wk | 10 (10) | 0 |
| Panretinal photocoagulation, No. (%)a | ||
| During follow-up vitrectomy | 32 (32) | 4 (4) |
| Outside follow-up vitrectomy | 0 | 1 (<1) |
| Had ≥1 intravitreous aflibercept injection, No. (%)b | 99 (99)c | 34 (32)d |
| No. of intravitreous aflibercept injections, mean (SD), wkb | ||
| Between 0 and <24 wk | 4.6 (1.3) | 0.3 (0.8) |
| Between 0 and 104 wk | 8.9 (4.6) | 2.3 (4.3) |
| No. of intravitreous aflibercept injections through 104 wk, No. (%)b | ||
| 0 | 1 (1)c | 71 (68) |
| 1-4 | 12 (12) | 11 (10) |
| 5-8 | 39 (39) | 12 (11) |
| 9-12 | 28 (28) | 6 (6) |
| ≥13 | 20 (20) | 5 (5) |
a
Excludes the initial vitrectomy and any procedures performed before or during the initial vitrectomy.
b
Includes the initial injection of aflibercept.
c
One participant refused treatment.
d
Twenty-one eyes (20%) received at least 1 aflibercept injection for center-involved diabetic macular edema; 20 eyes (19%) received at least 1 aflibercept injection for complications of proliferative diabetic retinopathy, which included vitreous hemorrhage.